Ruti Aga: Six Years, One Glucocorticoid, and a Prescription No Clinic Ever Issued

Ten September is the date I underlined before I read a line of the verdict. The Athletics Integrity Unit's statement landed on a Thursday; the arithmetic inside it was older and colder. A positive sample after a half marathon win in China in March. Provisional suspension from 10 September. Then six years: two for the presence of a prohibited substance, four for tampering. Ruti Aga, 32, Ethiopian, marathon. I ruled the grid by hand before I let a model speak — 1,140 passes and 41 turnovers at Eden Gardens in 2026, a 200m split ledger at Salt Lake the same week — so the first question here is not how long the ban is. It is what the ban is made of, and where the real inconsistency sits. The inconsistency is not in the number. It is in the substance. Nearly every report called methylprednisolone a prohibited steroid. It is not a steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and S9 is prohibited in-competition only, by injection, oral or rectal route. Anabolic steroids sit in S1, and the gap between the two classes is legal, not pedantic. A therapeutic knee injection given weeks out from a race is a lawful treatment. It becomes a violation only if residues are still present inside the competition window. That window is narrow and unforgiving. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. Anju taught me to move the ceiling when the wind moves; here the wind is replaced by route of administration and the clock. Same discipline, different column. Aga's record raises a separate question, and I will attach the asterisk before the number. Tokyo Marathon 2026 winner, three second places at World Marathon Majors. Berlin 2026 in roughly 2:18:34, Tokyo 2026 in roughly 2:20:40 — both figures come from external recall, not from the source document, and they stay asterisked until a meet sheet surfaces. What the source actually gives is this: she won a half marathon in China in March. No mark, no splits, no field strength. Which means the win tells us she had usable form and that the race had an elite field and a testing programme. It tells us nothing about how fast she was. The first ledger is the sanction arithmetic. Two plus four equals six. A two-year presence sanction is the standard outcome when the substance is Specified and intent is not established; four years is the Code's standard tampering sanction. Which means the panel declined the no-significant-fault mitigation that would have cut the presence penalty. Six years is not an exceptional sentence. It is the standard sum with exactly one concession removed. The second ledger is the story. The defence was a knee injury requiring an injection — mechanistically plausible, because intra-articular and peri-articular glucocorticoid treatment is ordinary sports medicine in distance runners. Three verification checks then failed independently: the clinic on the prescription did not exist; the author was a family member with no medical registration; and the claim that an old prescription pad from a former workplace had been used was explicitly disowned by that clinic. I opened the asterisk file before I trusted the clean split, and the same rule applies here. The root of this sanction is paper, not pharmacology. Had the treatment been genuine and documented, two lawful routes were open — a therapeutic use exemption, or a demonstrated route-and-timing explanation. Neither was taken. A prescription was manufactured instead. Split the file, and the story usually splits with it: here it divides into a substance with no proven endurance benefit and a document that was entirely fictional. The third ledger never appears in the statement. Medical governance inside East African road-running entourages is not a personal lapse but a structural vacuum. An athlete with a credentialed team physician does not need a forged pad. Chronic knee pathology in a high-mileage marathoner creates pressure to protect appearance-fee income, glucocorticoids are the cheapest available tool, and the surrounding network is informal. The forgery is downstream of that vacuum, not its cause. The fourth ledger is the stage. China's label races function as the income tier between Majors for East African marathoners: high appearance fees, low race counts, thin scrutiny. That same tier is now the AIU's highest-yield testing ground. The fee economy and the testing economy are colliding in the same races, and that collision is the most useful thing in this case — though it stays at medium-high confidence, because no statement says it. Now the part where I argue with my own conclusion. Six years for a substance with no proven endurance benefit reads oddly against proportionality. Four years is routine in anabolic cases; here you have two years for something lawful out of competition and four for paperwork. Some will call it AIU rigour, others inconsistent enforcement against African road runners. I will not rule on either, because I have one case, not a category — inferring a trend from a single file is the same error as declaring a golden generation off one good meet. But one claim I will defend: what made this six years was the prescription, not the substance. And the media's share belongs on the record. Calling it a steroid told readers this was a performance case. It is a document-fraud case with a legitimate medical tool caught inside it. Route and timing were the two words that decided everything, and neither appeared in most coverage. One proportionality question stays open. Whether the March result and its prize money were annulled is not stated. Standard practice disqualifies the competition at which the sample was collected, but standard practice and a reasoned decision are not the same document, and I do not treat them as one. Six years at 32 means a return at 38. Ethiopian women's marathon depth is such that a 38-year-old with a doping history is not selectable at the margins, so the 2028 cycle is closed. What survives is the archive: the 2026 Tokyo title and three Major second places. The archive remembers what the highlight reel forgets. The next thing worth watching is not the length of the next ban. It is where the enforcement frontier is moving — from detection to document verification. When the first violation in a cluster of cases starts being outweighed by the second, fabricated explanation, the question becomes how many more pads are coming out of the same informal network, and how many have not yet been opened.